A Phase 2A Clinical Trial of EPI-743 (Vincerinone) on Visual Function in Friedreich's Ataxia Patients With Point Mutations
Latest Information Update: 10 Jan 2019
At a glance
- Drugs Vatiquinone (Primary)
- Indications Friedreich's ataxia
- Focus Adverse reactions; Therapeutic Use
- 28 Jun 2016 Status changed from active, no longer recruiting to completed.
- 21 Apr 2016 Results assessing neurologic functions presented at the 68th Annual Meeting of the American Academy of Neurology
- 02 Apr 2015 Planned primary completion date changed from 1 Jul 2015 to 1 Nov 2016 as reported by ClinicalTrials.gov